Amgenâ€™s Q1 2008 results show a slight revenue decline, primarily driven by significant drops in Aranesp and EPOGEN sales, coupled with uncertainty around label changes. While there is growth in products like ENBREL and Sensipar, the concerns over key drug performances and ongoing legal issues likely overshadow positive aspects in the short term. This mixed outlook suggests potential short-term market pressure on the stock.

[-1]